JP2025512025A - 抗cd40抗体及びその使用 - Google Patents

抗cd40抗体及びその使用 Download PDF

Info

Publication number
JP2025512025A
JP2025512025A JP2024560259A JP2024560259A JP2025512025A JP 2025512025 A JP2025512025 A JP 2025512025A JP 2024560259 A JP2024560259 A JP 2024560259A JP 2024560259 A JP2024560259 A JP 2024560259A JP 2025512025 A JP2025512025 A JP 2025512025A
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
amino acid
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512025A5 (cg-RX-API-DMAC7.html
Inventor
ヤーツイ リウ
マオポン ティエン
ファン ヤン
イー ヤン
Original Assignee
バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド filed Critical バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド
Publication of JP2025512025A publication Critical patent/JP2025512025A/ja
Publication of JP2025512025A5 publication Critical patent/JP2025512025A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024560259A 2022-04-15 2023-04-14 抗cd40抗体及びその使用 Pending JP2025512025A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/087003 2022-04-15
CN2022087003 2022-04-15
PCT/CN2023/088417 WO2023198194A1 (en) 2022-04-15 2023-04-14 Anti-cd40 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2025512025A true JP2025512025A (ja) 2025-04-16
JP2025512025A5 JP2025512025A5 (cg-RX-API-DMAC7.html) 2026-04-21

Family

ID=88329041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560259A Pending JP2025512025A (ja) 2022-04-15 2023-04-14 抗cd40抗体及びその使用

Country Status (7)

Country Link
EP (1) EP4508088A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025512025A (cg-RX-API-DMAC7.html)
KR (1) KR20250005109A (cg-RX-API-DMAC7.html)
CN (1) CN119110807A (cg-RX-API-DMAC7.html)
AU (1) AU2023254322A1 (cg-RX-API-DMAC7.html)
CA (1) CA3256072A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023198194A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053661A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
AU2016201742B2 (en) * 2010-11-15 2017-11-02 Novartis Ag Silent Fc variants of anti-CD40 antibodies
HUE065915T2 (hu) * 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
NO2699601T3 (cg-RX-API-DMAC7.html) * 2011-04-21 2018-06-16
WO2020006347A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
WO2020014974A1 (en) * 2018-07-20 2020-01-23 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2023198194A1 (en) 2023-10-19
EP4508088A4 (en) 2026-04-01
CN119110807A (zh) 2024-12-10
KR20250005109A (ko) 2025-01-09
CA3256072A1 (en) 2023-10-19
AU2023254322A1 (en) 2024-10-24
EP4508088A1 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
US20240352141A1 (en) Anti-ox40 antibodies and uses thereof
WO2020001344A1 (en) ANTI-CD3e ANTIBODIES AND USES THEREOF
US20250034271A1 (en) Anti-cd40 antibodies and uses thereof
WO2020253722A1 (en) Anti-cd40 antibodies and uses thereof
CA3116564A1 (en) Anti-pd-1 antibodies and uses thereof
US20250019454A1 (en) Anti-tnfr2 antibodies and uses thereof
WO2023198194A1 (en) Anti-cd40 antibodies and uses thereof
WO2024175020A1 (en) Anti-il2ra antibodies and uses thereof
WO2022037672A1 (en) Anti-cd47 antibodies and uses thereof
HK40117288A (en) Anti-cd40 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260413